A simple blood test may soon help doctors find many cancers before symptoms begin

A new federal law could change the future of cancer care in the United States, especially for older adults and communities that often struggle to get early screenings.

In February 2026, President Donald Trump signed the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act into law. The measure allows Medicare to begin covering new blood tests that may help detect several types of cancer earlier than ever before. Supporters say the law could help save lives by finding cancer before it spreads.

The tests are called multi-cancer early detection tests, also known as MCED tests. Unlike a mammogram or colonoscopy, which usually look for one type of cancer, these blood tests are designed to search for signals from many cancers at the same time. Scientists hope the tests will help doctors find cancers that are normally hard to detect early, including pancreatic, ovarian, and liver cancer.

The Prevent Cancer Foundation called the law “a historic moment for cancer prevention and early detection.” The organization said the law creates a path for Medicare to cover these tests once they are approved by the U.S. Food and Drug Administration. 

Cancer remains one of the leading causes of death in the United States. According to the American Cancer Society, more than 2 million new cancer cases are expected in 2026. Yet routine screening is available for only a small number of cancers today. Many deadly cancers are often found too late, after the disease has already spread.

That problem has hit Black, Latino, Native, and rural communities especially hard. Many families face barriers such as high medical costs, lack of transportation, fewer nearby clinics, and lower access to preventive care. Research from the Centers for Disease Control and Prevention has shown that Black Americans are more likely to die from certain cancers than white Americans, even when rates of diagnosis are similar.

Health experts believe earlier testing could help narrow some of those gaps.

“This law aligns our health care system with the pace of scientific innovation,” said Jody Hoyos, chief executive officer of the Prevent Cancer Foundation. She said the goal is to create “a future where more cancers are found earlier—when treatment is more effective and lives can be saved.” 

The new law does not mean these blood tests will become available overnight. Right now, no MCED test has full FDA approval for nationwide Medicare coverage. Several companies are still studying the tests in large clinical trials. Some versions are already being offered privately, but experts say more evidence is needed before the tests become part of standard care.

Under the law, Medicare coverage is expected to begin as early as 2028 or 2029 after federal review. The coverage will start with certain age groups and expand over time. Medicare beneficiaries will likely be able to receive one test each year.

Lawmakers from both political parties supported the measure. Representative Terri Sewell of Alabama and Representative Jodey Arrington of Texas helped lead the effort in Congress. Senator Michael Bennet of Colorado said the technology could offer “new hope to millions of Americans.” 

Doctors say the tests could become especially important in neighborhoods where people often skip preventive care because of cost, fear, or lack of time. A simple blood draw may feel easier and less invasive than some traditional screenings. That could encourage more people to get checked before they become sick.

Still, health experts caution that these new tests are not replacements for mammograms, Pap smears, prostate exams, or colon cancer screenings. The law specifically states that MCED tests are meant to work alongside existing cancer screenings, not replace them. 

There are also concerns about making sure the tests work equally well for all racial and ethnic groups. In the past, some medical studies included too few Black and Latino patients. That raised fears about whether new technologies would be accurate for everyone.

Researchers say they are trying to avoid those mistakes. Many ongoing studies now include more diverse patient groups. Cancer advocates argue that equal access must remain a major part of the conversation as the technology moves forward.

The financial impact could also be significant. Cancer treatment often becomes more expensive when the disease is found late. Some experts believe earlier diagnosis could reduce hospital stays, emergency care, and long-term treatment costs. Exact Sciences, a company developing one MCED test, said its technology could potentially reduce late-stage cancer diagnoses by 45 percent when used alongside standard screenings. 

For families who have lost loved ones to cancer, the law represents hope that future generations may have better chances of survival. Many advocates say the measure is about more than technology. They say it is about giving people more time with their families and communities.

The coming years will determine how quickly the science advances and how broadly the tests become available. But for now, health leaders say the new law marks an important step toward a future where a simple blood test could help detect cancer earlier, reduce health disparities, and save lives across every community in America.